Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/21506| Title: | Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents. | Austin Authors: | Sasadeusz, Joe;Grigg, Andrew P ;Hughes, Peter D;Lee Lim, Seng;Lucas, Michaela;McColl, Geoff;McLachlan, Sue Anne;Peters, Marion G;Shackel, Nicholas;Slavin, Monica;Sundararajan, Vijaya;Thompson, Alexander;Doyle, Joseph;Rickard, James;De Cruz, Peter;Gish, Robert G;Visvanathan, Kumar | Affiliation: | University of Queensland Oral Health Centre, 288 Herston Road, Queensland 4006, Australia University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia Burnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australia The Alfred and Monash University, 85 Commercial Road, Melbourne, Victoria 3004, Australia Department of Public Health, La Trobe University, Plenty Road, Bundoora, Victoria 3086, Australia Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia Ingham Institute, 1 Campbell Street, Liverpool, Sydney, North South Wales 2170, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Victoria 3000, Australia Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia National University of Singapore, 21 Lower Kent Ridge Road, Singapore 119077, Singapore University of California, San Francisco, S357 Parnassus Avenue, San Francisco, CA 94143, USA Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA Austin Health, Heidelberg, Victoria, Australia |
Issue Date: | Aug-2019 | metadata.dc.date: | 2019-06-05 | Publication information: | Clinics in liver disease 2019; 23(3): 521-534 | Abstract: | Because of the relatively high prevalence of both hepatitis B infection and various forms of autoimmune inflammatory diseases treated with aggressive immunotherapy, reactivation of hepatitis B occurs in a substantial number of patients. The risk of reactivation depends on the degree and duration of immunosuppression. A large number of drug treatments have resulted in reactivation of hepatitis B virus infection and, based on the mechanisms and extent of immunosuppression, recommendations for some of the newer classes of immunosuppressive drugs are provided. | URI: | http://ahro.austin.org.au/austinjspui/handle/1/21506 | DOI: | 10.1016/j.cld.2019.04.012 | PubMed URL: | 31266625 | Type: | Journal Article | Subjects: | Anti-CD20 Direct-acting antivirals Hepatitis B Inflammatory bowel diseases Reactivation Rheumatoid arthritis |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.